Roivant Alliance Takes SK Into Cancer, Intractable Diseases

Invests $200m In TPD Platform

 
• By Jung Won Shin
  
SK and Roivant's partnership
SK First Korean Firm To Enter US Targeted Protein Degradation Market • Source: SK Holdings
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia